Economic evaluation of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus

Vanni, Tázio

doi:10.1590/s1413-86702006000400001

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…De fato, a análise feita do exemplo em questão apenas considerou a cura clínica ou a morte (ver Figura 1 em Machado et al 22 ). Entre-tanto, ambos os tratamentos podem gerar efeitos adversos (Figura 2) que devem ser incorporados pois influenciam no custo total do tratamento por paciente 23 . Além do custo adicional, os efeitos adversos podem interferir na conseqüên-cia do tratamento, por exemplo, na qualidade de vida 24 .…”

Section: Principais Desenhos De Estudos Econômicosunclassified

Avaliação econômica em saúde: aplicações em doenças infecciosas

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Principais Desenhos De Estudos Econômicosunclassified

Avaliação econômica em saúde: aplicações em doenças infecciosas

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

A review of economic studies evaluating the treatment of ventilator associated pneumonia

Miranda

Silva

Simões

2023

Preprint

View full text Add to dashboard Cite

Background: The clinical definition of Ventilator Associated Pneumonia (VAP) is infection arising during intubation. The topic has attracted considerable interest as a subject of clinical efficacy research. Cost is an important factor when we consider similar options of antibiotic treatments. This study aims to review pharmacoeconomic evaluations made of different VAP treatments and summarize the evaluation methods utilized. Methods: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). The search strategy was created considering the “PICOS” question, and data was sourced from PubMed, LILACS, Web of Science and Scopus databases, on October 2022. Inclusion and exclusion criterials were applied to filter the results. Findings: The search resulted in 574 studies, of which 12 were used. Of these, four studies evaluated empirical therapy. Antibiotic analysis was performed in eight case studies of Gram-negative infections and four of Gram-positive spectrum. The most prevalent analysis mode was Cost-effectiveness. Cost-minimization, Cost-benefit and general costs comparison were also seen. Different modellings were applied when performing the pharmacoeconomic analysis, such as Tree decision, Markov cohort, as well as methodologies like discrete event micro simulation and sequential simulation. Monte Carlo simulation was then used in five studies to analyze model sensitivity. The Linezolid treatment was shown to be more cost-effective than vancomycin in MRSA pneumonia. Doripinem also showed similar behavior when compared to imipinem in all included studies. Ceftazidime-avibactam and ceftalozane-tazobactam presented an advantage in cost-effectiveness when compared with meropenem. Clarithromycin and ceftriaxone+sulbactam+disodiumedetate used in adjuvant treatments, promoted reduction of the costs in patients with A. baumannii. Meropenem-varbobactam was also found to be a cost-effective treatment option when compared with standard therapies used in patients with CRE-KPC infections. Conclusion: Even though many models were used in pharmacoeconomic evaluations for VAP, Cost-effectiveness was clearly the most prevalent one. In short, the studies showed an advantage when using new medications. Nonetheless, we must be cautious when interpreting such findings, since they reflect a different reality for each country. Long-term impact and resource availability should also be considered.

show abstract

Economic evaluation of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus

Cited by 2 publications

References 7 publications

Avaliação econômica em saúde: aplicações em doenças infecciosas

Avaliação econômica em saúde: aplicações em doenças infecciosas

A review of economic studies evaluating the treatment of ventilator associated pneumonia

Contact Info

Product

Resources

About